456 Studies Now Enrolling
A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas with Prior Exposure to Alkylating Agents
Study of Nivolumab (Study Drug) for Recurrent or Progressive IDH Mutant Gliomas
| Sponsor: | Bristol-Myers Squibb |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR6354 |
| U.S. Govt. ID: | NCT03557359 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to test how well the study drug works in recurrent or isocitratedehydrogenase (IDH) mutant high grade gliomas. The study drug is called Nivolumab. Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow your own body's immune system to work against tumor cells. Nivolumab is not approved for use for gliomas in the United States.
This study is closed
